[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema].

Tatsuro Ishibashi, Mitsuko Yuzawa, Nagahisa Yoshimura, Masahito Ohji, Susumu Ishida, Naoki Isogawa, Etsuko Esaka

研究成果: ジャーナルへの寄稿記事

3 引用 (Scopus)

抄録

To evaluate the efficacy and safety of intravitreal injections of pegaptanib sodium in subjects with diabetic macular edema (DME). There were 243 subjects with DME who were randomized to receive, every 6 weeks, either an intravitreal injection of pegaptanib sodium or a sham injection. The study was double-masked for the first 24 weeks, and then an open label phase continued to week 54. The primary efficacy endpoint was evaluated at week 24, and safety was assessed throughout the 54 weeks. The proportion of subjects who experienced more than 10 letters improvement of visual acuity in ETDRS chart from baseline to week 24 was statistically significantly greater (p-value = 0.0003) in the pegaptanib sodium group, 20.3%, than in the sham group, 5.0%. The incidence of treatment-related adverse events was similar between the treatment groups (pegaptanib sodium group: 10.6%, sham group: 10.0%). The reported adverse events were mainly mild or moderate ophthalmic events and related to the injection procedure. During open-label phase up to 54 weeks, no new safety concerns were identified compared with the double-masked phase. However, in light of the issue concerning proper maintenance of masking of the study treatments, the study was not considered as a well-controlled, double-masked study.

元の言語英語
ページ(範囲)773-782
ページ数10
ジャーナルNippon Ganka Gakkai zasshi
118
発行部数9
出版物ステータス出版済み - 1 1 2014

Fingerprint

Macular Edema
Japan
Intravitreal Injections
Safety
Double-Blind Method
Injections
Visual Acuity
Therapeutics
Maintenance
pegaptanib
Incidence

All Science Journal Classification (ASJC) codes

  • Medicine(all)

これを引用

Ishibashi, T., Yuzawa, M., Yoshimura, N., Ohji, M., Ishida, S., Isogawa, N., & Esaka, E. (2014). [Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema]. Nippon Ganka Gakkai zasshi, 118(9), 773-782.

[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema]. / Ishibashi, Tatsuro; Yuzawa, Mitsuko; Yoshimura, Nagahisa; Ohji, Masahito; Ishida, Susumu; Isogawa, Naoki; Esaka, Etsuko.

:: Nippon Ganka Gakkai zasshi, 巻 118, 番号 9, 01.01.2014, p. 773-782.

研究成果: ジャーナルへの寄稿記事

Ishibashi, T, Yuzawa, M, Yoshimura, N, Ohji, M, Ishida, S, Isogawa, N & Esaka, E 2014, '[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema].', Nippon Ganka Gakkai zasshi, 巻. 118, 番号 9, pp. 773-782.
Ishibashi T, Yuzawa M, Yoshimura N, Ohji M, Ishida S, Isogawa N その他. [Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema]. Nippon Ganka Gakkai zasshi. 2014 1 1;118(9):773-782.
Ishibashi, Tatsuro ; Yuzawa, Mitsuko ; Yoshimura, Nagahisa ; Ohji, Masahito ; Ishida, Susumu ; Isogawa, Naoki ; Esaka, Etsuko. / [Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema]. :: Nippon Ganka Gakkai zasshi. 2014 ; 巻 118, 番号 9. pp. 773-782.
@article{a733a53626574ef281ee564f1845d86e,
title = "[Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema].",
abstract = "To evaluate the efficacy and safety of intravitreal injections of pegaptanib sodium in subjects with diabetic macular edema (DME). There were 243 subjects with DME who were randomized to receive, every 6 weeks, either an intravitreal injection of pegaptanib sodium or a sham injection. The study was double-masked for the first 24 weeks, and then an open label phase continued to week 54. The primary efficacy endpoint was evaluated at week 24, and safety was assessed throughout the 54 weeks. The proportion of subjects who experienced more than 10 letters improvement of visual acuity in ETDRS chart from baseline to week 24 was statistically significantly greater (p-value = 0.0003) in the pegaptanib sodium group, 20.3{\%}, than in the sham group, 5.0{\%}. The incidence of treatment-related adverse events was similar between the treatment groups (pegaptanib sodium group: 10.6{\%}, sham group: 10.0{\%}). The reported adverse events were mainly mild or moderate ophthalmic events and related to the injection procedure. During open-label phase up to 54 weeks, no new safety concerns were identified compared with the double-masked phase. However, in light of the issue concerning proper maintenance of masking of the study treatments, the study was not considered as a well-controlled, double-masked study.",
author = "Tatsuro Ishibashi and Mitsuko Yuzawa and Nagahisa Yoshimura and Masahito Ohji and Susumu Ishida and Naoki Isogawa and Etsuko Esaka",
year = "2014",
month = "1",
day = "1",
language = "English",
volume = "118",
pages = "773--782",
journal = "Journal of Japanese Ophthalmological Society",
issn = "0029-0203",
publisher = "Nippon Ganka Gakkai",
number = "9",

}

TY - JOUR

T1 - [Japan phase 3 study of pegaptanib sodium in patients with diabetic macular edema].

AU - Ishibashi, Tatsuro

AU - Yuzawa, Mitsuko

AU - Yoshimura, Nagahisa

AU - Ohji, Masahito

AU - Ishida, Susumu

AU - Isogawa, Naoki

AU - Esaka, Etsuko

PY - 2014/1/1

Y1 - 2014/1/1

N2 - To evaluate the efficacy and safety of intravitreal injections of pegaptanib sodium in subjects with diabetic macular edema (DME). There were 243 subjects with DME who were randomized to receive, every 6 weeks, either an intravitreal injection of pegaptanib sodium or a sham injection. The study was double-masked for the first 24 weeks, and then an open label phase continued to week 54. The primary efficacy endpoint was evaluated at week 24, and safety was assessed throughout the 54 weeks. The proportion of subjects who experienced more than 10 letters improvement of visual acuity in ETDRS chart from baseline to week 24 was statistically significantly greater (p-value = 0.0003) in the pegaptanib sodium group, 20.3%, than in the sham group, 5.0%. The incidence of treatment-related adverse events was similar between the treatment groups (pegaptanib sodium group: 10.6%, sham group: 10.0%). The reported adverse events were mainly mild or moderate ophthalmic events and related to the injection procedure. During open-label phase up to 54 weeks, no new safety concerns were identified compared with the double-masked phase. However, in light of the issue concerning proper maintenance of masking of the study treatments, the study was not considered as a well-controlled, double-masked study.

AB - To evaluate the efficacy and safety of intravitreal injections of pegaptanib sodium in subjects with diabetic macular edema (DME). There were 243 subjects with DME who were randomized to receive, every 6 weeks, either an intravitreal injection of pegaptanib sodium or a sham injection. The study was double-masked for the first 24 weeks, and then an open label phase continued to week 54. The primary efficacy endpoint was evaluated at week 24, and safety was assessed throughout the 54 weeks. The proportion of subjects who experienced more than 10 letters improvement of visual acuity in ETDRS chart from baseline to week 24 was statistically significantly greater (p-value = 0.0003) in the pegaptanib sodium group, 20.3%, than in the sham group, 5.0%. The incidence of treatment-related adverse events was similar between the treatment groups (pegaptanib sodium group: 10.6%, sham group: 10.0%). The reported adverse events were mainly mild or moderate ophthalmic events and related to the injection procedure. During open-label phase up to 54 weeks, no new safety concerns were identified compared with the double-masked phase. However, in light of the issue concerning proper maintenance of masking of the study treatments, the study was not considered as a well-controlled, double-masked study.

UR - http://www.scopus.com/inward/record.url?scp=84908645065&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908645065&partnerID=8YFLogxK

M3 - Article

C2 - 25318186

AN - SCOPUS:84908645065

VL - 118

SP - 773

EP - 782

JO - Journal of Japanese Ophthalmological Society

JF - Journal of Japanese Ophthalmological Society

SN - 0029-0203

IS - 9

ER -